Literature DB >> 6525991

The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments.

R Peto, M C Pike, L Bernstein, L S Gold, B N Ames.   

Abstract

A generally accepted format for the numerical description of the carcinogenic potency of a particular chemical in a particular strain of animals is desirable so that statements from different sources about potency and attempts by different authors to correlate potency with particular laboratory measurements will be comparable. The choice of an appropriate standard format is to a certain extent arbitrary. In this paper we recommend that the TD50 (tumorigenic dose rate 50) be used. TD50 can be calculated for a single target site or combination of sites. The TD50, in analogy with the LD50, is defined as that chronic dose rate (in mg/kg body weight/day) which would halve the actuarially adjusted percentage of tumor-free animals at the end of a standard experiment time--the "standard lifespan" for the species. This paper consists of a brief discussion of the TD50, sufficient to make the general reader familiar with the properties of such an index, an appendix discussing methods for its estimation and certain conventions we have adopted for use in analyzing "nonstandard" experiments. A major problem in calculating any index of carcinogenic potency is that much published material gives only the final crude percentage of tumor-bearing animals at each dose, instead of percentages adjusted for the effects of intercurrent mortality or data from which these adjusted percentages can be derived. If the dose level administered to the animals is toxic, then premature death from nonneoplastic causes may prevent some dosed animals that would have developed tumors from actually doing so. This will particularly affect the high-dose group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6525991      PMCID: PMC1569426          DOI: 10.1289/ehp.84581

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  6 in total

1.  Weibull distributions for continuous-carcinogenesis experiments.

Authors:  R Peto; P Lee
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

2.  Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments.

Authors:  R Peto; M C Pike; N E Day; R G Gray; P N Lee; S Parish; J Peto; S Richards; J Wahrendorf
Journal:  IARC Monogr Eval Carcinog Risk Chem Hum Suppl       Date:  1980

3.  Interspecies comparison of carcionogenic potency.

Authors:  E Crouch; R Wilson
Journal:  J Toxicol Environ Health       Date:  1979-11

4.  AN ACTUARIAL METHOD OF ANALYSIS OF AN EXPERIMENT IN TWO-STAGE CARCINOGENESIS.

Authors:  M C PIKE; F J ROE
Journal:  Br J Cancer       Date:  1963-12       Impact factor: 7.640

5.  A carcinogenic potency database of the standardized results of animal bioassays.

Authors:  L S Gold; C B Sawyer; R Magaw; G M Backman; M de Veciana; R Levinson; N K Hooper; W R Havender; L Bernstein; R Peto
Journal:  Environ Health Perspect       Date:  1984-12       Impact factor: 9.031

6.  The effect both of time and dose applied on tumour incidence rate in benzopyrene skin painting experiments.

Authors:  P N Lee; J A O'Neill
Journal:  Br J Cancer       Date:  1971-12       Impact factor: 7.640

  6 in total
  16 in total

1.  Evaluating Metabolite-Related DNA Oxidation and Adduct Damage from Aryl Amines Using a Microfluidic ECL Array.

Authors:  Itti Bist; Snehasis Bhakta; Di Jiang; Tia E Keyes; Aaron Martin; Robert J Forster; James F Rusling
Journal:  Anal Chem       Date:  2017-11-09       Impact factor: 6.986

2.  Low dose assessment of the carcinogenicity of furan in male F344/N Nctr rats in a 2-year gavage study.

Authors:  Linda S Von Tungeln; Nigel J Walker; Greg R Olson; Maria C B Mendoza; Robert P Felton; Brett T Thorn; M Matilde Marques; Igor P Pogribny; Daniel R Doerge; Frederick A Beland
Journal:  Food Chem Toxicol       Date:  2016-11-18       Impact factor: 6.023

3.  Microfluidic electrochemical array for detection of reactive metabolites formed by cytochrome P450 enzymes.

Authors:  Dhanuka P Wasalathanthri; Vigneshwaran Mani; Chi K Tang; James F Rusling
Journal:  Anal Chem       Date:  2011-11-15       Impact factor: 6.986

4.  Evaluation of electrochemiluminescent metabolic toxicity screening arrays using a multiple compound set.

Authors:  Shenmin Pan; Linlin Zhao; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2011-03-11       Impact factor: 6.986

5.  Use of Lhasa Limited Products for the In Silico Prediction of Drug Toxicity.

Authors:  David J Ponting; Michael J Burns; Robert S Foster; Rachel Hemingway; Grace Kocks; Donna S MacMillan; Andrew L Shannon-Little; Rachael E Tennant; Jessica R Tidmarsh; David J Yeo
Journal:  Methods Mol Biol       Date:  2022

6.  Developing Structure-Activity Relationships for N-Nitrosamine Activity.

Authors:  Kevin P Cross; David J Ponting
Journal:  Comput Toxicol       Date:  2021-09-08

7.  Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system.

Authors:  Dhanuka P Wasalathanthri; Ronaldo C Faria; Spundana Malla; Amit A Joshi; John B Schenkman; James F Rusling
Journal:  Analyst       Date:  2012-10-25       Impact factor: 4.616

8.  New public QSAR model for carcinogenicity.

Authors:  Natalja Fjodorova; Marjan Vracko; Marjana Novic; Alessandra Roncaglioni; Emilio Benfenati
Journal:  Chem Cent J       Date:  2010-07-29       Impact factor: 4.215

9.  Possible implications from results of animal studies in human risk estimations for benzene: nonlinear dose-response relationship due to saturation of metabolism.

Authors:  S Grilli; W K Lutz; S Parodi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

10.  Generation of TD50 values for carcinogenicity study data.

Authors:  Andrew Thresher; John Paul Gosling; Richard Williams
Journal:  Toxicol Res (Camb)       Date:  2019-07-25       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.